Bioresorbable Coronary Stents Market Size, Share & Trends Analysis Report By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The globalbioresorbable coronary stents market sizewas estimated atUSD 140.2 million in 2022and is anticipated to grow at a compound annual growth rate (CAGR) of 15.3% from 2023 to 2030. An increasing number of clinical trials, a growing geriatric population base, and an increasing incidence rate of coronary and peripheral artery diseases are some of the factors propelling the market growth. The placement of these bioresorbable devices enables individuals to live with a normal functioning artery as well as the option to undergo angioplasty in their later years. While still in the development stage, the pediatric patient cohort with genetic coronary conditions is a viable target for these fully dissolvable stents that allow restoration of normal vasomotor function and normal vessel growth.

Another key growth driver for this market is the increasing count of elective percutaneous coronary intervention (PCI) procedures, particularly in the Asia Pacific region. Cardiovascular diseases, a key driving factor for atherosclerosis, are increasing the worldwide stroke occurrence and coronary artery disease (CAD) rate. Risk factors associated with unhealthy lifestyles that are highly prevalent in urbanized regions underlie the stroke incidence rate, thus giving rise to a high demand for interventional coronary procedures among young adults.

The COVID-19 pandemic has significantly impacted the market. The healthcare industry faced numerous challenges during this unprecedented crisis. One notable pandemic effect was the postponement or cancellation of elective and non-urgent medical procedures, including冠状动脉支架植入。医院和的主要焦点healthcare facilities shifted towards treating COVID-19 patients and conserving resources, leading to a decrease in the number of procedures performed in 2020.

Furthermore, the pandemic disrupted global supply chains, causing difficulties in producing and distributing medical devices. Restrictions on international trade, lockdown measures, and the increased demand for medical supplies resulted in supply shortages. In addition, the fear of contracting the virus and restrictions on movement led to decreased patient visits to hospitals and clinics for routine check-ups and consultations.

Brand Insights

In terms of brand, the MeRes-100 segment held the largest revenue share of 24.7% in 2022. It received CE and DGCI marketing approval in 2019 and was backed by clinical trials that showed positive outcomes for patients with CAD. MeRes-100 is a bioresorbable scaffold, which is a non-permanent & metallic mesh tube and dissolves with time. It ensures the opening of previously blocked arteries via a routine angioplasty procedure. In March 2021, Meril Life Sciences announced its launch in 16 Indian cities, which has further propelled the segment growth.

In March 2020, the National Pharmaceutical Pricing Authority (NPPA) exempted it for 5 years under the “Drug Price Control Order 2013” provision. It has an exemption from price capping and authorities were directing Meril Life Sciences to inform them about the price of the stent that it intends to fix.

The increasing incidence rate of cardiovascular disease including CAD due to stressful and unhealthy lifestyles in developing economies such as India is expected to drive the market growth. The others segment including Absorb BVS and Absorb 2nd Generation is expected to grow at the fastest CAGR of 16.9% over the forecast period.

Regional Insights

North America dominated the market in 2022 with a revenue share of 37.4% owing to well-established healthcare infrastructure, including hospitals, clinics, and specialized cardiac centers, in the region. These facilities have state-of-the-art equipment and skilled healthcare professionals experienced in performing coronary interventions.

Asia Pacific (APAC) region is anticipated to grow at the fastest CAGR of 16.8% over the forecast period. Apart from increasing coronary stenting procedure volumes that stem from the high CVD-afflicted patient count, this region witnesses quick uptake of CE and FDA-approved devices. Moreover, the region has been investing in improving healthcare infrastructure, including developing modern hospitals, cardiac centers, and catheterization laboratories equipped with advanced medical technologies.

Key Companies & Market Share Insights

The key players are undertaking various strategies such as mergers & acquisitions, new product developments, collaborations & partnerships, and expansion strategies to improve their market penetration. For instance, in 2022, Biosensors International Group, an interventional cardiology devices manufacturer, announced the approval for BioFreedom. It is a drug-coated coronary stent system used to improve coronary luminal diameter in patients who are at a greater risk of bleeding. Some prominent participants in the global bioresorbable coronary stents market include:

• Boston Scientific Corporation

• Medtronic

• Abbott

• STENTYS

• Cordis

• Biotronik

• Lepu Medical Technology (Beijing) Co., Ltd.

• Cook

• XTENT

• Kyoto Medical Planning Co., Ltd.

Bioresorbable Coronary Stents MarketReport Scope

Report Attribute	Details
Market size value in 2023	USD 163.5 million
Revenue forecast in 2030	USD 442.9 million
Growth rate	CAGR of 15.3% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 - 2021
Forecast period	2023 - 2030
Report updated	September 2023
Quantitative units	Revenue in USD million and CAGR from 2023 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Brand, region
Regional scope	北美;欧洲;亚太地区;拉丁美洲; MEA
Country scope	U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
关键的公司介绍	Boston Scientific Corporation; Medtronic; Abbott; Stentys; Cordis; Biotronik; Lepu Medical Technology (Beijing) Co., Ltd.; Cook; XTENT; Kyoto Medical Planning Co., Ltd.
Customization scope	Free report customization (equivalent to up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.Explore purchase options

Global Bioresorbable Coronary Stents Market ReportSegmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the bioresorbable coronary stents market report based on brand and region:

• Brand Outlook (Revenue, USD Million, 2018 - 2030)

  • Magmaris

  • Magnitude

  • MeRes-100

  • DESolve

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • 意大利

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • 拉丁美洲

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait